# EDGAR Filing Document

**Accession Number:** 0001601936
**File Stem:** 0001213900-26-021580
**Filing Date:** 2026-2
**Character Count:** 3079
**Document Hash:** 0ec2ad23a17d6f98816052f3d89930c1
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001213900-26-021580.hdr.sgml**: 20260227

**ACCESSION NUMBER**: 0001213900-26-021580

**CONFORMED SUBMISSION TYPE**: 15-12G

**PUBLIC DOCUMENT COUNT**: 1

**FILED AS OF DATE**: 20260227

**DATE AS OF CHANGE**: 20260227

**EFFECTIVENESS DATE**: 20260227

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Altamira Therapeutics Ltd.
- **CENTRAL INDEX KEY:** 0001601936
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 000000000
- **STATE OF INCORPORATION:** D0
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 15-12G
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-36582
- **FILM NUMBER:** 26699675

**BUSINESS ADDRESS:**
- **STREET 1:** CLARENDON HOUSE
- **STREET 2:** 2 CHURCH STREET
- **CITY:** HAMILTON HM 11
- **STATE:** D0
- **ZIP:** 00000
- **BUSINESS PHONE:** 41 (0) 41 729 71 94

**MAIL ADDRESS:**
- **STREET 1:** CLARENDON HOUSE
- **STREET 2:** 2 CHURCH STREET
- **CITY:** HAMILTON HM 11
- **STATE:** D0
- **ZIP:** 00000

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** Auris Medical Holding Ltd.
- **DATE OF NAME CHANGE:** 20190318

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** Auris Medical Holding AG
- **DATE OF NAME CHANGE:** 20190314

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** Auris Medical Holding Ltd.
- **DATE OF NAME CHANGE:** 20190312

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**Washington, D.C. 20549**

**FORM 15**

**CERTIFICATION AND NOTICE OF TERMINATION OF REGISTRATION<br> UNDER SECTION 12(g) OF THE SECURITIES EXCHANGE ACT OF 1934<br> OR SUSPENSION OF DUTY TO FILE REPORTS UNDER SECTIONS 13 AND 15(d)<br> OF THE SECURITIES EXCHANGE ACT OF 1934**

**Commission File Number: 001-36582**

**Altamira Therapeutics Ltd.**

(Exact name of registrant as specified in its charter)

**Clarendon House**

**2 Church Street**

**Hamilton HM11**

**Bermuda**

**+1 (441) 295 59 50** 

(Address, including zip code, and telephone number, including area code, of registrant's principal executive offices)

**Common shares, par value $0.002 per share**

(Title of each class of securities covered by this Form)

**None**

(Titles of all other classes of securities for which a duty to file reports under section 13(a) or 15(d) remains)

Please place an X in the box(es) to designate the appropriate rule provision(s) relied upon to terminate or suspend the duty to file reports:

---

| | |
|:---|:---|
| Rule 12g-4(a)(1) | ☒ |
| Rule 12g-4(a)(2) | ☐ |
| Rule 12h-3(b)(1)(i) | ☒ |
| Rule 12h-3(b)(1)(ii) | ☐ |
| Rule 15d-6 | ☐ |
| Rule 15d-22(b) | ☐ |

---

Approximate number of holders of record of the common stock: **48**

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, Altamira Therapeutics Ltd. has caused this certification/notice to be signed on its behalf by the undersigned duly authorized person.

---

| | | |
|:---|:---|:---|
| Date: February 27, 2026 | By: | /s/ Thomas Meyer |
|  | Name: | Thomas Meyer |
|  | Title: | Chief Executive Officer |

---